Taxane-based regimens as adjuvant treatment for breast cancer: a retrospective study in egyptian cancer patients.

摘要: Background: To evaluate the impact of adding taxanes to anthracycline-based regimens in adjuvant setting localized young female breast cancer patients on overall survival (OS) and disease free (DFS). Materials Methods: This retrospective study included all who were candidates for chemotherapy presenting Kasr Al Ainy centre clinical oncology Cairo (Cairo Cure) period from January 2005 till December 2010. Results: Our 865 patients, 732 whom received anthracycline based 133 taxane regimens. The mean age was 39 years. After a median follow up 50 months DFS 48.4 months. Survival analysis indicated that tumor size (>5cm vs. <5cm) p=0.001), nodal involvement (Yes No) p=0.0001) pathology (invasive lobular ductal) p=0.048) affected DFS. As regards hormonal status, ER, PR HER 2neu positive had longer (p=0.001, 0.003, 0.106). On multivariate by lymph node (p=0.014, 0.007). Subgroup showed improvement arms treated with terms Her2neu, ER PR, but this not statistically significant. Conclusions: Adding anthracyclines is beneficial treatment among subgroups, especially higher risk groups .The type characteristics have direct effects